Sort   by:  
 Page size 
UnknownCanadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
Not available
S-EPMC7253730 | biostudies-literature
UnknownConsensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
Not available
S-EPMC9318743 | biostudies-literature
UnknownAnalysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.
Not available
S-EPMC11672496 | biostudies-literature
UnknownSurvival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index.
Not available
S-EPMC7050022 | biostudies-literature
UnknownPlasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.
Not available
S-EPMC9500258 | biostudies-literature
UnknownContinuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Not available
S-EPMC7676888 | biostudies-literature
UnknownProgrammed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
Not available
S-EPMC10514105 | biostudies-literature
UnknownBMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.
Not available
S-EPMC9579497 | biostudies-literature
UnknownClinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.
Not available
S-EPMC4800294 | biostudies-literature
UnknownLandscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Not available
S-EPMC12912800 | biostudies-literature
Sort   by:  
 Page size